abstract |
Contemplated methods and compositions include a pharmacological composition comprising an antigen and a nucleoside adjuvant that modulates the balance between Type 1 response and Type 2 response in a lymphocyte, wherein the nucleoside is not an 8-substituted guanine nucleoside. In preferred aspects, contemplated adjuvants stimulate Type 1 response and thereby increase a T-cell response, while contemplated adjuvants may also stimulate a Type 2 response and thereby increase a B-cell response. Preferred adjuvants may further comprise a CpG-dinucleotide and/or a CpG-containing oligonucleotide in a synergistic amount. |